Depression genes amplify women’s heart disease risk

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated promising safety in healthy adults without

CMS did not make a na­tion­al cov­er­age de­ter­mi­na­tion for PrEP by the ex­pect­ed date of Oct. 10, but a fi­nal de­ci­sion will be com­ing lat­er,

The new dosing option of ZOLADEX is aimed at pre and perimenopausal women with an increased recurrence or advanced breast cancer risk. Credit: Gorodenkoff /